Samsung Bioepis' Humira biosimilar approved both in high and low concentration in US
이 글자크기로 변경됩니다.
(예시) 가장 빠른 뉴스가 있고 다양한 정보, 쌍방향 소통이 숨쉬는 다음뉴스를 만나보세요. 다음뉴스는 국내외 주요이슈와 실시간 속보, 문화생활 및 다양한 분야의 뉴스를 입체적으로 전달하고 있습니다.
Hadrima is indicated for the treatment of autoimmune diseases such as rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis and plaque psoriasis, among others.
Hadlima was previously approved by the FDA as a low-concentration (50 mg/mL) formulation in July 2019. The latest approval enables availability in both low and high concentration adalimumab biosimilar.
Under a patent agreement with AbbVie, Hadlima is expected to be launched on or after July 2023 by Organon & Co. in the U.S.
Hadlima is marketed by Biogen under the trade name of Imraldi in Europe and by Yuhan under the trade name of Adalloce in Korea. It was launched in October 2018 in Europe and May 2021 in Korea, with over 5 million doses sold since 2018.
[ⓒ Maeil Business Newspaper & mk.co.kr, All rights reserved]
Copyright © 매일경제 & mk.co.kr. 무단 전재, 재배포 및 AI학습 이용 금지
- Of Kospi members, 12% earned more in OP H1 than full 2021 - Pulse by Maeil Business News Korea
- Naver under probe by law enforcement offices on multiple counts for abuse of power - Pulse by Maeil Business News Korea
- S. Korea’s top 50 biggest firms see 21% fall in operating cash flow in H1 - Pulse by Maeil Business News Korea
- Korea’s top 20 firms’ OP up 35% on average H1, hiring gain stops at 1.2% - Pulse by Maeil Business News Korea
- Samsung Elec, SK hynix, LG Elec up Capex, R&D spending in H1 - Pulse by Maeil Business News Korea
- 강경준, 상간남 피소…사랑꾼 이미지 타격 [MK픽] - 스타투데이
- 아시아 최초 ‘다인종·다문화 국가’ 한국 [편집장 레터]
- NCT 태일, 불미스러운 일로 팀 탈퇴…SM “엄중함 인지”[공식입장][전문] - MK스포츠
- 이찬원, 이태원 참사에 "노래 못해요" 했다가 봉변 당했다 - 스타투데이
- 양희은·양희경 자매, 오늘(4일) 모친상 - 스타투데이